GC- According to the Annual Report the clinical program planned...

GC- According to the Annual Report the clinical program planned for OxyC Topical is 2 x Phase 2 trials looking at two peripheral pain indications-these candidate pain indications for a topical pain patch are postherpetic neuralgia and osteoarthritis....while POHs previous trials have shown that OxyC can be delivered topically with little systemic spillage -the trials are designed to show whether it will be clinically efficacious- whether TPM OxyC can deliver effective pain relief. These OxyC trials should therefore require small enrolments and be cheap and quick.

OxyM on the other hand we were told at the AGM will require tox studies and then an IND to enable a large US trial- so its a longer road but with a high value prize. Given the OxyM Phase 2 Multi dose trials in Oct 13 produced results equal to those that could be expected from a Phase 2- the co is understandably bullish about its prospects for success